Literature DB >> 26125275

RLIP76 expression as a prognostic marker of breast cancer.

C-Z Wang1, P Yuan, B Xu, L Yuan, H-Z Yang, X Liu.   

Abstract

OBJECTIVE: RLIP (Ral-interacting protein)-76/RalBP11 (Ral-binding protein-1), a multifunctional protein and stress-inducible non-ABC transporter, have been proven to serve as a critical role in cancer development and progression; however, little is known about the pathological role of RLIP76 in breast cancer patients. The study aimed to determine the correlation between RLIP76 expression in breast cancer patient and clinical outcomes. PATIENTS AND METHODS: Using RT-PCR and Western blot, messenger RNA (mRNA) and protein expression of RLIP76 were determined in breast cancer and adjacent normal mammary tissues. The relationship of RLIP76 expression with clinical characteristics of 245 breast cancer patients was analyzed by immunohistochemistry.
RESULTS: In the present study, our results indicated that RLIP76 mRNA and protein were highly expressed in the breast cancer tissues while compared with adjacent normal mammary tissues and the correlation with RLIP76 protein expression was significantly associated with age (the non-ABC transporter, stage and the expression were significantly associated-T2 vs. T3-T4, p < 0.01), lymph node metastasis (N0-N1 vs. N2-N3, p < 0.01), and PR (positive vs. negative, p < 0.01) in breast cancer patients; furthermore, we also found that RLIP76 protein overexpression was an unfavorable prognostic factor in the patients suffered from breast cancer.
CONCLUSIONS: RLIP76 overexpression serves as an unfavorable prognostic biomarker in breast cancer patients.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26125275

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  13 in total

1.  Targeting RLIP with CRISPR/Cas9 controls tumor growth.

Authors:  Jyotsana Singhal; Shireen Chikara; David Horne; Sanjay Awasthi; Ravi Salgia; Sharad S Singhal
Journal:  Carcinogenesis       Date:  2021-02-11       Impact factor: 4.944

Review 2.  Regulatory roles of glutathione-S-transferases and 4-hydroxynonenal in stress-mediated signaling and toxicity.

Authors:  Yogesh C Awasthi; Kota V Ramana; Pankaj Chaudhary; Satish K Srivastava; Sanjay Awasthi
Journal:  Free Radic Biol Med       Date:  2016-10-26       Impact factor: 7.376

3.  Clinical significance of SPRY4-IT1 in efficacy and survival prediction in breast cancer patients undergoing neoadjuvant chemotherapy.

Authors:  Ang Zheng; Lin Zhang; Xinyue Song; Feng Jin
Journal:  Histol Histopathol       Date:  2019-10-22       Impact factor: 2.303

Review 4.  RLIP76 Inhibition: A Promising Developmental Therapy for Neuroblastoma.

Authors:  Sharad S Singhal; Lokesh Nagaprashantha; Preeti Singhal; Sulabh Singhal; Jyotsana Singhal; Sanjay Awasthi; David Horne
Journal:  Pharm Res       Date:  2017-04-06       Impact factor: 4.200

5.  Synergistic efficacy of RLIP inhibition and 2'-hydroxyflavanone against DMBA-induced mammary carcinogenesis in SENCAR mice.

Authors:  Sharad S Singhal; David Horne; Jyotsana Singhal; Steven Vonderfecht; Ravi Salgia; Sanjay Awasthi
Journal:  Mol Carcinog       Date:  2019-04-21       Impact factor: 4.784

6.  RLIP depletion induces apoptosis associated with inhibition of JAK2/STAT3 signaling in melanoma cells.

Authors:  Sharad S Singhal; Atish Mohanty; Prakash Kulkarni; David Horne; Sanjay Awasthi; Ravi Salgia
Journal:  Carcinogenesis       Date:  2021-05-28       Impact factor: 4.944

7.  Prevention of mammary carcinogenesis in MMTV-neu mice by targeting RLIP.

Authors:  Jyotsana Singhal; Prakash Kulkarni; David Horne; Sanjay Awasthi; Ravi Salgia; Sharad S Singhal
Journal:  Mol Carcinog       Date:  2021-02-05       Impact factor: 4.784

8.  RLIP inhibition suppresses breast-to-lung metastasis.

Authors:  Jyotsana Singhal; Shireen Chikara; David Horne; Ravi Salgia; Sanjay Awasthi; Sharad S Singhal
Journal:  Cancer Lett       Date:  2019-01-23       Impact factor: 8.679

9.  Metastasis of breast tumor cells to brain is suppressed by targeting RLIP alone and in combination with 2'-Hydroxyflavanone.

Authors:  Jyotsana Singhal; Preeti Singhal; David Horne; Ravi Salgia; Sanjay Awasthi; Sharad S Singhal
Journal:  Cancer Lett       Date:  2018-09-15       Impact factor: 8.679

10.  2'-Hydroxyflavanone inhibits in vitro and in vivo growth of breast cancer cells by targeting RLIP76.

Authors:  Jyotsana Singhal; Shireen Chikara; David Horne; Ravi Salgia; Sanjay Awasthi; Sharad S Singhal
Journal:  Mol Carcinog       Date:  2018-09-19       Impact factor: 4.784

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.